Eli Lilly Bets Billions on Unapproved Weight-Loss Pill with Major Texas Facility
Published on 09/25/2025 at 14:54 | Redaktion boerse-global.de
Eli Lilly is making an unprecedented $6.5 billion wager on a single facility in Texas, dedicated to a drug that has not yet received regulatory approval. This record-breaking investment is centered on the company’s experimental oral weight-loss medication, Orforglipron, raising questions about the viability of such a high-stakes strategy.
The new Houston plant is designed to become the primary manufacturing hub for Orforglipron. This oral GLP-1 agonist is positioned as a convenient alternative to Lilly’s successful injectable treatments, Mounjaro and Zepbound. This project is a key component of a much larger, $27 billion capital expenditure plan to establish four new US-based sites over the next five years.
The scale of the Texas investment is significant, promising to create 600 permanent... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
